1. Charles Hodge Charles Hodge United States says:

    "Evidence for any adverse or beneficial clinical impact of either ACEi or ARB, together or separately, when used in COVID-19 patients either as part of an ongoing protocol or as a newly initiated treatment, is lacking. "


    What's the point of this "news" article then?

    Rediculous. 🙄

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.